La vendita allo scoperto per Humana dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Humana. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Humana (NYSE:HUM) Azioni, Report sulle vendite allo scoperto

Humana

Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Humana Inc

Humanscape

Humacyte Inc

Humble & Fume Inc

Anthropos Capital Corporation

Hua Medicine

Humm Group Ltd

Humble Energy Inc

HUMMINGBIRD RES LTD ORD by Hummingbird Resources Ltd

Hummingbird Resources PLC

Humatech Inc

During the last three months, 23 analysts shared their evaluations of Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">17</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $297.17, with a high estimate of $400.00 and a low estimate of $247.00. A 19.56% drop is evident in the current average compared to the previous average price target of $369.41. 
<img src="https://www.benzinga.com/files/images/story/2024/1730754056_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Humana by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$268.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$290.00</td>
<td>$387.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$253.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$260.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$250.00</td>
<td>$364.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Lance Wilkes</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$308.00</td>
<td>-</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$265.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$261.00</td>
<td>$402.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$253.00</td>
<td>$419.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$250.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$274.00</td>
<td>$392.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$250.00</td>
<td>$349.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$247.00</td>
<td>$376.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$250.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$250.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$395.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$395.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$395.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$396.00</td>
<td>$332.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$395.00</td>
<td>$395.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Humana. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Humana compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Humana's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Humana's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HUM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Humana analyst ratings.</a>
<h2>Unveiling the Story Behind Humana</h2>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Humana's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Humana's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 11.26%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Humana's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 1.63%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.8%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Humana's ROA excels beyond industry benchmarks, reaching 0.96%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.74, caution is advised due to increased financial risk.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

The Latest Analyst Ratings For Humana

TD Cowen analyst Gary Taylor maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Hold and raises the price target from $261 to $268.

News

Price Target

TD Cowen Maintains Hold on Humana, Raises Price Target to $268

Wells Fargo analyst Stephen Baxter maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Overweight and lowers the price target from $387 to $290.

Wells Fargo Maintains Overweight on Humana, Lowers Price Target to $290

Barclays analyst Andrew Mok maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Equal-Weight and raises the price target from $250 to $253.

Barclays Maintains Equal-Weight on Humana, Raises Price Target to $253

Wednesday,&nbsp;Humana Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) posted third-quarter adjusted EPS of $4.16, down from $7.78 a year ago, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $3.40</a>.
The company reported revenues of $29.30 billion, up 14.7% year-over-year from $25.53 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41619980/humana-reports-third-quarter-2024-financial-results-updates-full-year-adjusted-2024-financial-guid" rel="noreferrer noopener">consensus of $28.67 billion</a>, primarily driven by higher per-member Medicare premiums and Medicare Advantage and state-based contracts membership growth.
Humana&nbsp;ended the third quarter with 16.358 million in total medical membership, compared to 16.963 million a year ago.
Medicare Advantage membership&nbsp;<a target="_blank" href="https://humana.gcs-web.com/static-files/9de77655-133d-44b7-8812-b1e7e15a0c47" rel="noreferrer noopener">reached</a> 5.659 million, up from 5.374 million a year ago.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41429974/cigna-and-humana-revive-early-merger-talks-after-year-long-pause-as-medicare-cost-pressure-looms" rel="noreferrer noopener">Cigna And Humana Revive Early Merger Talks After Year-Long Pause As Medicare Cost Pressure Looms</a>
The benefit ratio increased to 89.9% from 86.6% a year ago. The company, in its prepared <a target="_blank" href="https://humana.gcs-web.com/static-files/b42403eb-ea20-46d2-a9e5-729f706c7947" rel="noreferrer noopener">remarks</a>, said the benefit ratio was slightly better than expectations for the third quarter, driven by outperformance in CenterWell Primary Care.
The insurance segment benefit ratio reached 90.6% from 87.6%, in line with the company&#8217;s expectations, supported by slightly higher-than-anticipated member risk scores and in line medical costs in Medicare Advantage business, offset by higher-than-anticipated Medicaid medical costs.
Guidance: Humana raised its 2024 individual Medicare Advantage annual membership growth expectations by 40,000 to 265,000, driven by better-than-expected retention and non-DSNP sales compared to prior guidance of 225,000.
Humana Sees 2024 GAAP EPS of at least $12.89 versus prior guidance of approximately 12.81 compared to the consensus of $13.36.
The insurance giant expects adjusted EPS of at least $16 compared to <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/40070046/insurance-giant-humana-stock-tumbles-after-q2-earnings-beat-issues-sub-par-profit-outlook" rel="noreferrer noopener">prior guidance of around $16.00</a> and a consensus of $16.17.
The company states it is aiming for a Medicare Advantage margin target of at least 3%, though it acknowledges that reaching this goal by 2027 may now be more challenging due to the impact of the <a target="_blank" href="https://www.benzinga.com/government/24/10/41140319/humana-faces-sharp-decline-in-medicare-star-ratings-for-2025-braces-for-2026-revenue-hit" rel="noreferrer noopener">2025 MA Star ratings</a>.
For 2024, Humana reaffirms its insurance segment&#8217;s benefit ratio guidance of approximately 90%, with 91.5%-92% for the fourth quarter.
&#8220;We expect 2025 Adjusted EPS to be at least in line with final 2024 results inclusive of these investments, and provided our 2025 membership change is in line with current expectations,&#8221; Humana&nbsp;<a target="_blank" href="https://humana.gcs-web.com/static-files/b42403eb-ea20-46d2-a9e5-729f706c7947" rel="noreferrer noopener">said</a>.
Price Action: HUM stock is up 3.47% at $266.72 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua" target="_blank" rel="noreferrer noopener">Eli Lilly Q3 Earnings: Mounjaro Sales More Than Double, Takes $2.98 Billion Hit To Profit, Cuts Annual Outlook, Stock Tanks</a></li>
</ul>
Photo: T. Schneider via Shutterstock

Earnings

Large Cap

Guidance

Health Care

General

Humana Lifts 2024 Profit Outlook As Q3 Earnings Beat Street View On Medicare Strength

Humana Exec Says Company Will Approach 2025 With "Similar Posture" As Q3 Strategy

WIIM

Humana shares are trading higher after the company reported better-than-expected Q3 adjusted EPS and sales.

Humana Sees 2024 GAAP EPS Of At Least $12.89 Versus Prior Guidance Of ~12.81 Vs $13.36 Estimate; Sees Adjusted EPS Of At Least $16 Compared To Prior Guidance Of ~$16.00 Vs $16.17 Estimate

Humana Reports Q3 Adjusted Benefits Expense Ratio Of 89.8% Versus 86.4% A Year Ago

Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) reported quarterly earnings of $4.16 per share which beat the analyst consensus estimate of $3.40 by 22.35 percent. This is a 46.53 percent decrease over earnings of $7.78 per share from the same period last year. The company reported quarterly sales of $29.30 billion which beat the analyst consensus estimate of $28.67 billion by 2.20 percent. This is a 14.78 percent increase over sales of $25.53 billion the same period last year.

Earnings Beats

Humana Q3 2024 Adj EPS $4.16 Beats $3.40 Estimate, Sales $29.30B Beat $28.67B Estimate

Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) has outperformed the market over the past 15 years by 1.4% on an annualized basis producing an average annual return of 13.49%. Currently, Humana has a market capitalization of $31.22 billion. 
Buying $100 In HUM: If an investor had bought $100 of HUM stock 15 years ago, it would be worth $688.29 today based on a price of $259.28 for HUM at the time of writing.
<h3>Humana's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730217619_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $100 In This Stock 15 Years Ago, You Would Have $700 Today

In its upcoming report, Humana (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hum#NYSE">HUM</a>) is predicted by Wall Street analysts to post quarterly earnings of $3.48 per share, reflecting a decline of 55.3% compared to the same period last year. Revenues are forecasted to be $28.66 billion, representing a year-over-year increase of 12.3%.
The current level reflects an upward revision of 1.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company&#39;s earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts&#39; projections for specific key metrics can offer valuable insights.
Bearing this in mind, let&#39;s now explore the average estimates of specific Humana metrics that are commonly monitored and projected by Wall Street analysts.
According to the collective judgment of analysts, &#39;Revenues- Premiums&#39; should come in at $27.28 billion. The estimate indicates a change of +8.7% from the prior-year quarter.
Analysts forecast &#39;Revenues- Investment income (loss)&#39; to reach $303.08 million. The estimate suggests a change of -1.6% year over year.
The consensus estimate for &#39;Revenues- Services&#39; stands at $1.06 billion. The estimate suggests a change of +4.5% year over year.
The consensus among analysts is that &#39;Revenue- CenterWell&#39; will reach $4.84 billion. The estimate points to a change of +3.8% from the year-ago quarter.
The average prediction of analysts places &#39;Benefits Expense Ratio - Consolidated&#39; at 90.0%. The estimate compares to the year-ago value of 86.6%.
Based on the collective assessment of analysts, &#39;Medical Membership - Group Medicare Advantage&#39; should arrive at 547.91 thousand. The estimate compares to the year-ago value of 510.3 thousand.
Analysts&#39; assessment points toward &#39;Medical Membership - Medicare stand-alone PDP&#39; reaching 2,296.84 thousand. The estimate compares to the year-ago value of 2.89 million.
The collective assessment of analysts points to an estimated &#39;Medical Membership - Individual Medicare Advantage&#39; of 5,613.68 thousand. Compared to the present estimate, the company reported 5.37 million in the same quarter last year.
Analysts expect &#39;Medical Membership - Total Medicare&#39; to come in at 8,458.44 thousand. Compared to the present estimate, the company reported 8.77 million in the same quarter last year.
The combined assessment of analysts suggests that &#39;Medical Membership- State-based contracts and other&#39; will likely reach 1,432.88 thousand. The estimate compares to the year-ago value of 1.26 million.
Analysts predict that the &#39;Medical Membership - Medicare Supplement&#39; will reach 334.07 thousand. Compared to the current estimate, the company reported 299.4 thousand in the same quarter of the previous year.
It is projected by analysts that the &#39;Medical Membership - Military services&#39; will reach 5,956.46 thousand. The estimate compares to the year-ago value of 5.94 million.
<a href="https://www.zacks.com/stock/news/2358419/what-analyst-projections-for-key-metrics-reveal-about-humana-hum-q3-earnings?cid=CS-BENZ-FT-fundamental_analysis|nfm_preview-2358419">To read this article on Zacks.com click here.</a>

Markets

What Analyst Projections For Key Metrics Reveal About Humana Q3 Earnings

Investors with a lot of money to spend have taken a bearish stance on Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HUM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Humana.
This isn't normal.
The overall sentiment of these big-money traders is split between 12% bullish and 50%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $419,512, and 6 are calls, for a total amount of $216,146.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $240.0 and $290.0 for Humana, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Humana's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Humana's significant trades, within a strike price range of $240.0 to $290.0, over the past month.
<h3>Humana 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730125834_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$20.1</td>
<td>$19.3</td>
<td>$20.0</td>
<td>$255.00</td>
<td>$384.2K</td>
<td style="text-align: right;">38</td>
<td style="text-align: right;">153</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$72.0</td>
<td>$64.0</td>
<td>$64.0</td>
<td>$240.00</td>
<td>$44.8K</td>
<td style="text-align: right;">14</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/01/24</td>
<td>$10.8</td>
<td>$10.1</td>
<td>$10.4</td>
<td>$260.00</td>
<td>$44.7K</td>
<td style="text-align: right;">252</td>
<td style="text-align: right;">47</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$67.4</td>
<td>$61.2</td>
<td>$62.5</td>
<td>$250.00</td>
<td>$37.5K</td>
<td style="text-align: right;">99</td>
<td style="text-align: right;">20</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/08/24</td>
<td>$15.0</td>
<td>$13.6</td>
<td>$14.57</td>
<td>$265.00</td>
<td>$35.3K</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">25</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Having examined the options trading patterns of Humana, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Humana Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 232,475, the HUM's price is up by 1.2%, now at $263.87. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 2 days.</li>
</ul>
<h3>Professional Analyst Ratings for Humana</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $251.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from B of A Securities downgraded its rating to Underperform, setting a price target of $247. 
&#x2A; An analyst from Stephens &amp; Co. has revised its rating downward to Equal-Weight, adjusting the price target to $250. 
&#x2A; In a cautious move, an analyst from Leerink Partners downgraded its rating to Market Perform, setting a price target of $250. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Hold rating on Humana with a target price of $260. 
&#x2A; Consistent in their evaluation, an analyst from Deutsche Bank keeps a Hold rating on Humana with a target price of $250. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Humana options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Unpacking the Latest Options Trading Trends in Humana

Including Indiana, Iowa, Kentucky, Louisiana, New Mexico, Tennessee, Washington, And West Virginia, Starting In 2025

Humana And Longevity Health Expand Access To Humana Together In Health Special Needs Plans Across Eight States

Financial giants have made a conspicuous bearish move on Humana. Our analysis of options history for Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) revealed 9 unusual trades.
Delving into the details, we found 22% of traders were bullish, while 44% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $128,992, and 7 were calls, valued at $293,298.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $250.0 to $310.0 for Humana during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Humana stands at 93.0, with a total volume reaching 224.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Humana, situated within the strike price corridor from $250.0 to $310.0, throughout the last 30 days.
<h3>Humana 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729611936_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$15.0</td>
<td>$14.1</td>
<td>$14.9</td>
<td>$272.50</td>
<td>$74.5K</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">51</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$26.8</td>
<td>$26.7</td>
<td>$26.7</td>
<td>$250.00</td>
<td>$66.7K</td>
<td style="text-align: right;">183</td>
<td style="text-align: right;">20</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$23.0</td>
<td>$21.8</td>
<td>$21.8</td>
<td>$310.00</td>
<td>$65.4K</td>
<td style="text-align: right;">62</td>
<td style="text-align: right;">45</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/08/24</td>
<td>$16.1</td>
<td>$14.9</td>
<td>$15.55</td>
<td>$260.00</td>
<td>$62.2K</td>
<td style="text-align: right;">62</td>
<td style="text-align: right;">45</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/25/24</td>
<td>$8.6</td>
<td>$7.1</td>
<td>$7.73</td>
<td>$255.00</td>
<td>$35.5K</td>
<td style="text-align: right;">134</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Present Market Standing of Humana</h3>
<ul>
<li>Currently trading with a volume of 376,521, the HUM's price is up by 0.95%, now at $263.05. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 8 days.</li>
</ul>
<h3>Expert Opinions on Humana</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $257.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Truist Securities persists with their Hold rating on Humana, maintaining a target price of $260. 
&#x2A; In a cautious move, an analyst from B of A Securities downgraded its rating to Underperform, setting a price target of $247. 
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Humana, which currently sits at a price target of $280. 
&#x2A; Reflecting concerns, an analyst from Stephens &amp; Co. lowers its rating to Equal-Weight with a new price target of $250. 
&#x2A; Consistent in their evaluation, an analyst from Deutsche Bank keeps a Hold rating on Humana with a target price of $250. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Humana with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

U.S. major indices fell on Monday as rising Treasury yields and a strengthening dollar dampened risk sentiment. Investors are reassessing the economic outlook and weighing potential risks tied to the Federal Reserve&#8217;s <a href="https://www.benzinga.com/topic/interest-rates">next interest rate moves.</a>
Yields on the 10-year Treasury note surged 9 basis points to 4.18%, reaching their highest level since late July. Meanwhile, 30-year Treasury bond yields climbed to 4.5%. The spike in yields pushed the iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) down by 1.4%, reflecting renewed pressure on long-duration bonds.
A gauge of the greenback, as tracked by Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), rose 0.5%. 
On Monday, Dallas Fed President Lorie Logan hinted that gradual rate cuts are on the cards if the economy meets forecasts. Market-implied expectations for a 25-basis-point rate cut in November dipped slightly from 90% to 85%, according to CME FedWatch.
The CBOE Volatility Index (VIX), commonly known as Wall Street's "fear gauge," jumped 5% on Monday, marking its largest surge in two weeks.
The S&amp;P 500 traded 0.5% lower at midday trading in New York, with all its 11 sectors in the red. The Dow Jones Industrial Average shed 0.9%, while the Russell 2000, which tracks small-cap stocks, tumbled 1.7%. Technology stocks experienced minor losses. 
Despite the negative session, NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) gained over 2%, hitting $141.80 per share and notching fresh all-time highs.
In commodities, gold took a breather after four consecutive sessions of gains, while oil prices rebounded 1.6%, driven by renewed supply concerns. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell sharply, losing 2.8%. 
<h1 class="wp-block-heading">Monday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,290.48</td>
<td>-0.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,840.64</td>
<td>-0.4%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,904.60</td>
<td>-0.9%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,237.90</td>
<td>-1.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:55 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent101824&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.3% to $582.24.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;fell 0.7% to $429.46.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) eased 0.2% to $493.66.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) dipped to $222.12.</li>
<li>The Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) outperformed, up 0.9%. The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 0.6%.</li>
</ul>
<h1 class="wp-block-heading">Monday&#8217;s Stock Movers</h1>
<ul>
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) surged over 3% after the company reached a preliminary agreement with its employees to end a five-week strike. Adding to the momentum, Emirates SkyCargo placed an order for five additional Boeing 777 freighters. </li>
<li>Kenvue Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) shares jumped 6.5% following reports that activist investor Starboard Value has acquired a substantial stake in the company.</li>
<li>Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) extended its losses on Monday, falling nearly 5% after a 5% decline on Friday, as investors continued to react negatively to reports of a potential merger with Humana Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>). Oppenheimer analysts weighed in on the situation, recommending that Cigna remain independent amid skepticism about the merger's strategic value and regulatory feasibility.</li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41431485/goldman-sachs-predicts-bleak-long-term-s-p-500-returns-as-market-concentration-hits">Goldman Sachs Predicts Bleak Long-Term S&amp;P 500 Returns As Market Concentration Hits &#8216;Highest Level In 100 Years&#8217;</a></li>
</ul>
Photo: Shutterstock

Equities

Sector ETFs

Bonds

Broad U.S. Equity ETFs

Currency ETFs

Forex

Treasuries

Econ #s

Federal Reserve

Tech

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

KVUE

NVDA

iShares Trust Barclays 20+ Year Treasury Bond Fund

PowerShares DB US Dollar Index Bullish Fund

Stocks Fall As Treasury Yields, Dollar Rise; Nvidia Hits Record Highs: What's Driving Markets Monday?

In a significant development in the health insurance industry, Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has reinitiated discussions to merge with Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), potentially creating a giant in the sector.
Talks, previously stalled over pricing disagreements, have resumed with a focus on a transformative consolidation that could reshape market dynamics.
According to a <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-10-18/cigna-resumes-merger-discussions-with-humana-after-talks-ended-last-year?sref=TBDibEcD" rel="noreferrer noopener">Bloomberg</a> report on Friday, the early talks about the merger would significantly expand Cigna&#8217;s footprint in Medicare Advantage alongside its commercial insurance prowess while leveraging Humana&#8217;s strong Medicare segment.
Also: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" rel="noreferrer noopener">US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth&#8217;s Pharmacy Benefit Managers For Inflating Insulin Prices</a>
Last year, both <a target="_blank" href="https://www.benzinga.com/markets/equities/23/11/36007194/whats-going-on-with-healthcare-insurance-giant-cigna-stock-today" rel="noreferrer noopener">companies faced challenges</a> as they navigated federal pressures to reduce Medicare costs, severely impacting Humana&#8217;s market performance and valuation.
These resumed talks hint at a possible major realignment aiming to fortify their positions against competitors like UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) and&nbsp;CVS Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>).
The merger discussions are still in the nascent stages, with no decisions made. Both companies declined to comment on the ongoing negotiations.
A potential deal, estimated to be among the top five health insurance mergers, reflects a strategic shift in the industry focused on consolidation amid rising healthcare costs and stringent regulatory environments.
This deal could not only stabilize Humana&#8217;s declining Medicare enrollments but also enhance Cigna&#8217;s capabilities in managing more comprehensive healthcare plans.
Furthermore, a merger could ease the competitive pressure from the rapidly growing sectors of the industry, providing a robust challenge to established giants.
Humana&#8217;s stock value sharply declined due to lower-than-expected government reimbursements and increased demand for medical services. The merger is, therefore, potentially crucial for recovery and growth.
Price Action: CI stock is down 4.18% at $321.94, and HUM stock is up 0.88% at $269.50 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41409405/after-failed-confirmatory-trial-gilead-withdraws-us-accelerated-approval-of-trodelvy-as-bladder-c" target="_blank" rel="noreferrer noopener">After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer Treatment</a>.</li>
</ul>
Photo via Shutterstock

Rumors

Movers

Media

Cigna And Humana Revive Early Merger Talks After Year-Long Pause As Medicare Cost Pressure Looms

Humana shares are trading higher after a report suggesting Cigna has resumed merger discussions with the company.

With U.S. stock futures trading mixed this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) to report quarterly earnings at $1.33 per share on revenue of $9.29 billion after the closing bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. SAP shares gained 0.2% to $230.87 in after-hours trading.</li>
<li>Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) named Chris Sambar as COO. Public Storage shares gained 0.1% to close at $345.62 on Friday.</li>
<li>Analysts are expecting Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) to post quarterly earnings at $1.47 per share on revenue of $7.28 billion. The company will release earnings after the markets close. Nucor shares gained 0.1% to close at $158.24 on Friday.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) shares fell in after-hours trading after a report suggesting the company has resumed merger discussions with Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) after the conversation ended last year. Cigna shares fell 4.7% to $320.26 in the after-hours trading session.</li>
<li>Analysts expect Logitech International S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) to report quarterly earnings at 99 cents per share on revenue of $1.11 billion after the closing bell. Logitech shares rose 1.2% to close at $88.63 on Friday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41402086/wall-streets-most-accurate-analysts-give-their-take-on-3-financials-stocks-delivering-hi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Financials Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo courtesy: SAP

Pre-Market Outlook

LOGI

SAP, Nucor And 3 Stocks To Watch Heading Into Monday

Humana shares are trading higher after a report suggesting Cigna has resumed merger discussions with the company after the conversation ended last year.

Humana (HUM) has disclosed a new risk, in the Litigation & Legal Liabilities category. Humana faces a significant business risk as its Medicare Adv...

Humana's Medicare Advantage Star Ratings Drop: Legal Battle Looms Over 2025 Projections and Potential Revenue Impact

In a report released today, Andrew Mok CFA from Barclays maintained a Hold rating on Humana (HUM – Research Report), with a price target of $253.00...

Barclays Sticks to Their Hold Rating for Humana (HUM)

In a report released yesterday, Steve Baxter from Wells Fargo maintained a Buy rating on Humana (HUM – Research Report), with a price target of $38...

Humana's Strong Q3 Performance and Strategic Margin Recovery Plan Earns Buy Rating

Humana drops amid Cigna comments on using cash for buybacks; may dampen takeover spec

TD Cowen analyst Ryan Langston maintained a Hold rating on Humana (HUM – Research Report) today and set a price target of $268.00. Ryan Langston ha...

Humana's Strategic Investments and Market Challenges Justify Hold Rating Amidst Uncertain Growth Prospects

In a report released on October 31, Ben Hendrix from RBC Capital maintained a Buy rating on Humana (HUM – Research Report), with a price target of ...

RBC Capital Keeps Their Buy Rating on Humana (HUM)

Wells Fargo analyst Stephen Baxter lowered the firm's price target on Humana (HUM) to $290 from $387 and keeps an Overweight rating on the shares. ...

Humana price target lowered to $290 from $387 at Wells Fargo

In a report released yesterday, Steve Baxter from Wells Fargo maintained a Buy rating on Humana (HUM – Research Report), with a price target of $29...

Wells Fargo Sticks to Its Buy Rating for Humana (HUM)

Bearish flow noted in Humana (HUM) with 32,655 puts trading, or 7x expected. Most active are 11/8 weekly 190 puts and 11/8 weekly 230 puts, with to...

Comments

Humana

Vendite allo scoperto

Humana (NYSE:HUM) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO